Advertisement

Document › Details
PhoreMost Ltd.. (11/9/20). "Press Release: PhoreMost and Oxford Biomedica Enter Gene Therapy Discovery Collaboration". Cambridge & Oxford.
>Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability
> PhoreMost’s SITESEEKER platform will identify active peptides to be deployed within Oxford Biomedica’s LentiVector delivery system
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica (UK) Ltd plc (LSE:OXB) (“Oxford Biomedica”), a leading gene and cell therapy group, today announced that they have entered into a discovery collaboration to develop next generation CAR-T cell therapies. Financial details of the agreement are not disclosed.
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system. The programme will initially focus on CAR-T therapy and aims to develop next generation cell therapies with significantly improved efficacy and durability.
“This collaboration with Oxford Biomedica, a global pioneer in cell and gene therapies, is further recognition of the power of SITESEEKER, offering an exciting opportunity to discover and accelerate the development of clinical stage products. The natural complementarity between SITESEEKER and LentiVector offers great promise for this and future collaborations between the two companies.”
Dr Chris Torrance, CEO, PhoreMost, said
“We are excited to apply this next-generation technology to our LentiVector platform. The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team.”.
John Dawson, CEO of Oxford Biomedica, said
SITESEEKER exploits protein shape diversity to find functionally active peptides linked to any chosen disease setting, significantly enhancing the power of phenotypic screening and translation into therapeutic modalities. Based on proprietary protein interference, or ‘PROTEINi®’, technology, SITESEEKER is able to systematically probe the entire proteome in a live cell environment to identity and exploit novel drug targets.
Oxford Biomedica is a world-leading pioneer of cell and gene therapies. Its LentiVector platform enables the successful development of breakthrough gene and cell-based medicines, and through collaborations with pharmaceutical partners, has delivered the first FDA and EMA approved CAR-T cell therapy.
Media enquiries
Zyme Communications:
Katie Odgaard
[email protected]
Phone: +44 (0)7787 502 947
At PhoreMost Ltd:
Dr Neil Torbett, CBO
[email protected]
Phone: +44 (0)1223 804 161
For Oxford Biomedica plc
John Dawson, Chief Executive Officer
Phone: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer
Phone: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR
[email protected]
Phone: +44 (0)1865 954 161
Mary-Jane Elliott/Matthew Neal
Consilium Strategic Communications
Phone: +44 (0)20 3709 5700
Record changed: 2024-12-23 |
Advertisement

More documents for PhoreMost Ltd.
- [1] PhoreMost Ltd.. (9/10/24). "Press Release: PhoreMost Extends Series B Financing to $50M to Advance High-value Oncology and Inflammation Degrader Programmes". Cambridge....
- [2] PhoreMost Ltd.. (6/3/24). "Press Release: PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim". Cambridge....
- [3] PhoreMost Ltd.. (1/5/23). "Press Release: PhoreMost Reaches Milestone in a Target Discovery Alliance with Boehringer Ingelheim". Cambridge....
- [4] PhoreMost Ltd.. (12/14/22). "Press Release: PhoreMost and ThinkCyte Collaborate to Advance AI Based Drug Discovery". Cambridge....
- [5] PhoreMost Ltd.. (10/28/22). "Press Release: PhoreMost Enters Multi-target Collaboration with Targeted Protein Degradation Leader Arvinas". Cambridge....
- [6] PhoreMost Ltd.. (9/6/22). "Press Release: PhoreMost Enters Multi-project Drug Target Discovery Collaboration with Roche". Cambridge....
- [7] PhoreMost Ltd.. (3/1/22). "Press Release: PhoreMost Promotes Dr Neil Torbett to Chief Executive Officer". Cambridge....
- [8] PhoreMost Ltd.. (1/5/22). "Press Release: PhoreMost and POLARISqb Announce a Multi-target Collaboration to Investigate Next-generation Cancer Therapies". Cambridge & Durham, NC....
- [9] PhoreMost Ltd.. (3/23/21). "Press Release: PhoreMost Closes £33M ($46M) Series B Financing". Cambridge....
- [10] PhoreMost Ltd.. (9/8/20). "Press Release: PhoreMost and XtalPi Sign AI-based Pharmaceutical drug Discovery Collaboration Agreement". Cambridge & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top